29 September 2014 : Review article
Primary Biliary Cirrhosis in the Era of Liver Transplantation
Joanna RaczyńskaBDEF, Andrzej HabiorACDEF, Leszek PączekBDEF, Bartosz ForoncewiczBDEF, Andrzej PawełasAE, Krzysztof MuchaABDEFDOI: 10.12659/AOT.890753
Ann Transplant 2014; 19:488-493
Abstract
Primary biliary cirrhosis (PBC) is an autoimmune disease of the liver, characterized by the presence of antimitochondrial antibodies (AMA) and progressive immune-mediated destruction of biliary ductules, which lead to cirrhosis. Theories of the PBC etiopathogenesis assume that the disease develops secondarily as an improper immunological reaction to undefined environmental and/or infectious factors in genetically predisposed individuals. Ursodeoxycholic acid (UDCA) is the only drug recommended to treat PBC; it delays the progression of liver disease, but remains only a symptomatic treatment. In the advanced stage of PBC, the treatment of choice is liver transplantation (LTx). Nowadays, PBC is the third indication for LTx, after viral-related and alcoholic liver cirrhosis. Unfortunately, PBC recurs in 21–37% of patients at 10 years after LTx, and in 43% at 15 years after LTx, with the median time to recurrence of 3–5.5 years. Diagnosis of recurrent PBC (rPBC) is based on the liver histopathology. Although various risk factors of rPBC have been investigated, the cause of the recurrence is not clear. There is no specific treatment of rPBC. Together with immunosuppression after LTx, UDCA remains the treatment of choice. New diagnostic technologies (e.g., genomics, proteomics, cell-based therapy, and clinical study of the rPBC patients) may be helpful in understanding the pathogenesis of PBC and the development of new treatment modalities.
Keywords: Genome-Wide Association Study, Immunosuppression, Liver Cirrhosis, Biliary, Liver Transplantation, Recurrence
In Press
Original article
Living Donor Liver Transplantation with Small Left Lobe Grafts: Prospective Validation of Utility of Splene...Ann Transplant In Press; DOI: 10.12659/AOT.946374
Original article
A New Routine Immunity Score (RIS2020) to Predict Severe Infection in Solid-Organ Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.946233
Original article
Survival Analysis of Liver Transplants in Patients with Acute Liver Failure from Acetaminophen and Mushroom...Ann Transplant In Press; DOI: 10.12659/AOT.946485
Original article
Medication Adherence Among Pediatric Post-Heart Transplant Patients in a Tertiary Care HospitalAnn Transplant In Press; DOI: 10.12659/AOT.946905
Most Viewed Current Articles
03 Jan 2023 : Original article 6,339
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...DOI :10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
16 May 2023 : Original article 6,002
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...DOI :10.12659/AOT.939258
Ann Transplant 2023; 28:e939258
15 Aug 2023 : Review article 5,852
Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ TransplantationDOI :10.12659/AOT.939750
Ann Transplant 2023; 28:e939750
17 Jan 2023 : Original article 5,139
Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation i...DOI :10.12659/AOT.938595
Ann Transplant 2023; 28:e938595